Orforglipron in Canada

Orforglipron in Canada, start to finish

This is the long version of the orforglipron Canada story, written for Canadians who keep hearing about a GLP-1 pill and want to know what it means for them. Each part below gives you the short answer, then points to the page on this site that covers it in depth. Let's break it down.

What orforglipron is

Orforglipron is a once-daily tablet that acts on the same GLP-1 receptor as Ozempic, Wegovy and the rest of the class. The difference is the shape of the molecule. Semaglutide and tirzepatide are peptides, short chains of amino acids that stomach acid tears apart, which is why most of them are injections. Orforglipron is a small, non-peptide chemical that survives the trip through the gut and gets absorbed like an ordinary pill.

That matters for daily life more than it sounds. The US label for Foundayo lets people take it at any time of day, with or without a meal. The only GLP-1 tablet sold in Canada today, oral semaglutide, comes with strict fasting rules every single morning.

Eli Lilly developed it under the code LY3502970 and tested it in a large phase 3 programme in people with obesity and with type 2 diabetes. For how it works, where it came from and why earlier pills in this class stalled, read our plain-language orforglipron explainer.

What the trials showed

The headline study is ATTAIN-1, published in the New England Journal of Medicine. Adults with obesity and without diabetes on the top dose lost an average of 12.4% of their body weight over 72 weeks, against under 1% on placebo. In people who also had type 2 diabetes (ATTAIN-2, in The Lancet), the average on the top dose was 10.5%. Smaller losses in diabetes show up with every GLP-1, so that gap is expected.

Our take: be careful with the league tables you will see online. No trial has tested orforglipron head to head against any injectable GLP-1, and trials differ in who they enrol and how they count people who stop early. Any ranking built by lining up separate studies is a rough guide, not a verdict.

Where orforglipron stands in Canada right now

Short answer: orforglipron in Canada is under review, not approved. Health Canada accepted Eli Lilly Canada's submission into review in January 2026. It shows up on Health Canada's own list of new drug submissions under review as a new active substance, flagged for an aligned review with a health technology assessment body.

That aligned review is happening at Canada's Drug Agency (CDA-AMC), which runs two separate orforglipron files: one for weight management and one for type 2 diabetes. Both are recorded as Pre-NOC, meaning Health Canada has not yet issued its Notice of Compliance. You can follow the weight management file on the CDA-AMC project page.

Here is why the CDA-AMC schedule is worth watching. The next published Canadian date is October 28, 2026 (Expert committee meets on weight management). After that, a draft reimbursement recommendation is due around November 9, 2026, and the agency cannot release one until Health Canada has authorised the drug. We read that as a hint that a Canadian decision could come late in 2026. It is a reading of a published schedule, not a promise from Lilly or Health Canada, and review clocks do pause.

The full dated chronology, including how Health Canada's 300-day review standard works, sits on our orforglipron approval timeline. What has to happen between approval and a stocked pharmacy shelf, province by province, is covered in Foundayo in Canada.

Why approval will not mean pharmacies have it the next day

Authorisation and supply are separate events. Wegovy was authorised in Canada in November 2021 and only reached Canadian pharmacies in May 2024. Zepbound, another Lilly product, took about eight weeks. Lilly has a recent record of moving fast in Canada, which counts for something, but we would not bet on a date until the company names one.

What orforglipron could cost Canadians

Nobody knows yet what orforglipron in Canada will cost, and any Canadian-dollar price you see quoted today is made up. What we do have is the US picture. Lilly's own cash prices for Foundayo run from US$149 to US$299 a month depending on the dose, and its published list price is US$649 a month, which almost no one actually pays.

Canada sets prices differently. After approval, a federal board reviews the price of patented drugs, Canada's Drug Agency makes a reimbursement recommendation, the provinces negotiate as a group, and then each public plan decides on its own. Obesity drugs have done badly at the public-plan stage, so Canadians using them have mostly relied on private insurance or paid out of pocket. Our orforglipron price breakdown walks through every dose and every step of the Canadian process.

Orforglipron side effects at a glance

The side effect profile looks like the rest of the GLP-1 class, mostly stomach and bowel trouble that tends to show up while the dose is being raised. In ATTAIN-1:

• Nausea affected up to 35.9% of people on orforglipron, against 10.4% on placebo.
• Constipation, diarrhea and vomiting were each reported by somewhere between a fifth and three in ten people on the two higher doses.
• Across the two weight trials, 8% stopped because of a side effect, compared with 3% on placebo.

The US label also carries a boxed warning about thyroid C-cell tumours seen in rodents with this class of drug, plus warnings on pancreatitis and gallbladder problems. FDA reviewers looked hard at liver safety, because several earlier pills of this type were dropped over liver signals, and found no strong evidence of a problem. The rates by dose, and what the label says about each warning, are on our orforglipron side effects guide.

How orforglipron compares with GLP-1 drugs sold in Canada

You do not have to wait for orforglipron to get a GLP-1 in Canada. Here is how it lines up against what a Canadian prescriber can already write today.

Generics are the big Canadian twist. Health Canada became the first G7 regulator to approve a generic semaglutide in April 2026, and in June it approved the first generic for weight loss, with more under review. Health Canada says generics in Canada tend to cost 45% to 90% less than the brand. By the time orforglipron reaches Canadian pharmacies, it may be competing with cheaper versions of the injection it is usually measured against.

The one direct comparison that exists is ACHIEVE-3, a 52-week trial against Rybelsus in adults with type 2 diabetes. Stomach side effects and dropouts were higher on orforglipron. Our Foundayo vs Rybelsus comparison goes through the results, the dosing rules and what the numbers do and do not tell you.

What Canadians can do about orforglipron now

Next steps, in the order we would take them:

• Talk to your family doctor or a pharmacist about the GLP-1 options already approved here. If one suits you, waiting an unknown number of months for a pill has a real cost.
• Do not order "orforglipron" from a website. Anything sold to Canadians today has not been authorised here, and some sellers market raw powder as a research chemical.
• If you spend time in the United States or want to know the legal routes, our guide on how to get Foundayo covers US prescriptions, Health Canada's personal import rules and clinical trials.
• Check what your private drug plan covers for GLP-1s now. In our view, plans that cover Wegovy or Zepbound today are the likeliest to consider orforglipron later.
• Sign up for our approval alerts. We email when a Canadian step actually happens, and only then.

We think most Canadians will be better served by a clear yes or no from Health Canada than by any workaround. When that decision lands, we will update this page as soon as we can cite it.